INFI Share Price

Open 1.74 Change Price %
High 1.74 1 Day -0.02 -1.15
Low 1.69 1 Week -0.07 -3.91
Close 1.72 1 Month -0.43 -20.00
Volume 215233 1 Year -3.47 -66.86
52 Week High 5.79
52 Week Low 0.84
INFI Important Levels
Resistance 2 1.77
Resistance 1 1.75
Pivot 1.72
Support 1 1.69
Support 2 1.67
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
CLSN 0.23 -93.11%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)

INFI Technical Analysis 4
As on 26th May 2017 INFI Share Price closed @ 1.72 and we RECOMMEND Sell for LONG-TERM with Stoploss of 1.80 & Strong Sell for SHORT-TERM with Stoploss of 2.37 we also expect STOCK to react on Following IMPORTANT LEVELS.
INFI Target for May
1st Target up-side 3.11
2nd Target up-side 3.79
3rd Target up-side 4.47
1st Target down-side 1.19
2nd Target down-side 0.51
3rd Target down-side -0.17
INFI Other Details
Segment EQ
Market Capital 793739008.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.infi.com
INFI Address
INFI
780 Memorial Drive
Cambridge, MA 02139
United States
Phone: 617-453-1000
Fax: 617-453-1001
INFI Latest News
Interactive Technical Analysis Chart Infinity Pharmaceuticals, Inc. ( INFI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Infinity Pharmaceuticals, Inc.
INFI Business Profile
Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective inhibitor of heat shock protein 90 (Hsp90). The phosphoinositide-3-kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell surface receptors to downstream biochemical events. The Company�s lead development candidate in this program is IPI-145 a potent, oral inhibitor of Class I PI3K-delta,gamma for which clinical trials are conducted form both hematologic malignancies and inflammatory diseases. Hematologic malignancies are cancers of the blood or bone marrow and include leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL).